Correction: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Correction: Aurora kinase targeting in lung cancer reduces KRAS-induced transformation ; volume:23 ; number:1 ; day:9 ; month:3 ; year:2024 ; pages:1-4 ; date:12.2024
Molecular cancer ; 23, Heft 1 (9.3.2024), 1-4, 12.2024
- Urheber
-
Santos, Edmilson Ozorio dos
Carneiro-Lobo, Tatiana Correa
Aoki, Mateus Nobrega
Levantini, Elena
Bassères, Daniela Sanchez
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12943-024-01964-6
- URN
-
urn:nbn:de:101:1-2405122112316.113406051278
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:54 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Santos, Edmilson Ozorio dos
- Carneiro-Lobo, Tatiana Correa
- Aoki, Mateus Nobrega
- Levantini, Elena
- Bassères, Daniela Sanchez
- SpringerLink (Online service)
Ähnliche Objekte (12)
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
Targeting neoepitopes derived from KRAS mutations for cancer-specific immunotherapy
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models
Targeting neoepitopes derived from KRAS mutations for cancer-specific immunotherapy
Aurora kinase targeting in lung cancer reduces KRAS-induced transformation
Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Expressionsanalyse von Aurora-Kinase A, Aurora-Kinase B, Repp 86, Cyclin-Dependent-Kinase 1 und Cyclin-Dependent-Kinase 2 bei Mamma- und Ovarialkarzinomen
Targeting mutant KRAS in pancreatic cancer: futile or promising?
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
Targeting focal adhesion kinase boosts immune response in KRAS/LKB1 co-mutated lung adenocarcinoma via remodeling the tumor microenvironment
Aurora kinase inhibitors: Progress towards the clinic
Editorial: Targeting bruton tyrosine kinase
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models